Commodore Capital LP 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Commodore Capital LP disclosed 36 US equity positions worth $1.6bn in its Q3 2024 13F filing. The largest position was MERUS N V at 10.5% of the reported book, followed by VERA and XENE.
What did Commodore Capital LP own in Q3 2024? Top 36 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | MERUS N V | 10.5% | $167.4m | 3,350,000 | – | ||
| 2 | VERA VERA THERAPEUTICS INC | Healthcare | 6.8% | $109.4m | 2,475,000 | – | |
| 3 | XENE XENON PHARMACEUTICALS INC | Healthcare | 6.6% | $106.3m | 2,700,000 | – | |
| 4 | PCVX VAXCYTE INC | Healthcare | 6.6% | $105.1m | 920,000 | – | |
| 5 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 6.5% | $104.7m | 4,100,000 | – | |
| 6 | NUVALENT INC | 6.0% | $96.2m | 940,000 | – | ||
| 7 | COGT COGENT BIOSCIENCES INC | Healthcare | 5.1% | $81.4m | 7,539,930 | – | |
| 8 | ALKS ALKERMES PLC | Healthcare | 5.1% | $81.2m | 2,900,000 | – | |
| 9 | SLNOEUR SOLENO THERAPEUTICS INC | 4.0% | $63.6m | 1,260,000 | – | ||
| 10 | SYRE SPYRE THERAPEUTICS INC | 3.7% | $58.5m | 1,988,084 | – | ||
| 11 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 3.6% | $58.0m | 2,550,124 | – | |
| 12 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 3.4% | $55.0m | 1,618,937 | – | |
| 13 | BRD1EUR MIND MEDICINE MINDMED INC | 2.8% | $45.5m | 8,000,000 | – | ||
| 14 | CATX PERSPECTIVE THERAPEUTICS INC | 2.8% | $44.7m | 3,350,000 | – | ||
| 15 | NRIX NURIX THERAPEUTICS INC | Healthcare | 2.3% | $37.1m | 1,650,000 | – | |
| 16 | PHVS PHARVARIS N V | 2.2% | $35.4m | 1,911,433 | – | ||
| 17 | KURA KURA ONCOLOGY INC | Healthcare | 2.2% | $35.2m | 1,800,000 | – | |
| 18 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 2.1% | $34.1m | 650,000 | – | |
| 19 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.1% | $33.6m | 1,369,714 | – | |
| 20 | ARVN ARVINAS INC | Healthcare | 1.8% | $29.6m | 1,200,000 | – | |
| 21 | CELC CELCUITY INC | Healthcare | 1.4% | $22.7m | 1,522,332 | – | |
| 22 | CNTA CENTESSA PHARMACEUTICALS PLC | 1.3% | $21.6m | 1,350,000 | – | ||
| 23 | NKTX NKARTA INC | Healthcare | 1.3% | $21.1m | 4,662,073 | – | |
| 24 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.3% | $20.5m | 2,000,000 | – | |
| 25 | CCCC C4 THERAPEUTICS INC | Healthcare | 1.2% | $19.4m | 3,410,384 | – | |
| 26 | THIRD HARMONIC BIO INC | 1.2% | $18.4m | 1,360,569 | – | ||
| 27 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.1% | $17.0m | 885,000 | – | |
| 28 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.1% | $17.0m | 290,000 | – | |
| 29 | ABVX ABIVAX SA | 0.9% | $14.8m | 1,284,110 | – | ||
| 30 | TIL INSTIL BIO INC | 0.6% | $10.2m | 150,929 | – | ||
| 31 | NGNE NEUROGENE INC | 0.5% | $8.4m | 200,000 | – | ||
| 32 | PERCEPTIVE CAP SOLUTIONS COR | 0.5% | $7.5m | 750,000 | – | ||
| 33 | HELIX ACQUISITION CORP II | 0.3% | $5.2m | 500,000 | – | ||
| 34 | CABA CABALETTA BIO INC | Healthcare | 0.3% | $5.2m | 1,100,000 | – | |
| 35 | VTGN VISTAGEN THERAPEUTICS INC | 0.3% | $4.7m | 1,575,000 | – | ||
| 36 | AVTX AVALO THERAPEUTICS INC | Healthcare | 0.3% | $4.6m | 483,000 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.